Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H3 mRNA Influenza Vaccine in Adults
NCT05829356Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised trial of H3 mRNA/LNP Vaccine in influenza (6 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events at 30 minutes, Number of participants with solicited injection site or systemic reaction at 7 days and 10 more. Started Apr 2023; status: completed.
02
Drugs
H3 mRNA/LNP Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05829356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829356.